Developer of Immune Cell Therapeutics
Click to follow and get more exciting content!

“Magnolia Award"One of the series of awards for foreign recognition in Shanghai, aiming to honor and encourage foreign individuals who have made outstanding contributions to Shanghai's economic construction, social development, and foreign relations. The Foreign Affairs Office of the Shanghai Municipal Government awarded 50 outstanding foreign individuals from 15 countries this afternoon. Thank you for their contributions to Shanghai!

Dr. Lixun Wang (third from the right), Founder, Chairman and CEO of Xingyiang (Shanghai) Biotechnology Co., Ltd.
Dr. Wang Liqun, founder, chairman, and CEO of Xingyiang (Shanghai) Biotechnology Co., Ltd., is one of this year's 50 awardees.Winners from fields such as trade, finance, technology, shipping, education, healthcare, and culture have leveraged their strengths to make outstanding contributions in various positions toward Shanghai's efforts to deepen the construction of the "five centers," strengthen the "four major functions," and advance high-level reform, opening up, and high-quality development. They are not only witnesses to Shanghai’s development but also active participants and promoters. The Shanghai municipal government expressed gratitude for their efforts and hopes that, through the Magnolia Awards series, more international talents will be inspired to come to Shanghai, stay in Shanghai, and integrate into Shanghai, supporting the city’s accelerated development into a socialist modern international metropolis with global influence.
XingyiangFocus on iPSC-derived CAR-NK advanced technology, Innovating at the source from two major aspects: product and process development,Development of Universal, Mass-Produced, Next-Generation Immune Cell Products for Solid Tumor Treatment, filling the global gap, significantly reducing the production cost of cellular products, and increasing the coverage of indications to provide accessible and affordable high-quality cellular drugs for cancer patients worldwide, establishing China's leading position. The company has currently obtained four software copyright patents, has seven national invention patents pending approval, and two PCT filings. It has completed two rounds of financing totaling 98 million US dollars. Within less than three years of its establishment, the candidate product is about to enter clinical validation.
THE END
No.1 Entrepreneurs Club
No. 1 Entrepreneurs Club is an open platform for communication and cooperation initiated by the founders of SIMBAY PARK (Free Trade Zone No. 1) enterprises. It aims to unite independent innovation companies within the SIMBAY ecosystem, gather industry elites and resources, and build a platform connecting government and enterprises, technology & regulations, business management, and resource alignment, providing substantial assistance for members' entrepreneurship and company development. Relying on the advantageous resources of the SIMBAY ecosystem, the club focuses on entrepreneurs within the SIMBAY ecosystem, creating three major service sectors: "Enterprise·Home," "Career·Support," and "Startup·Win," making entrepreneurship and innovation easier.
